Positive Outcome in a Pregnancy with Anti-kell Alloimmunization Treated with Intravenous Immunglobulin and Therapeutic Plasma Exchange Despite Persistence of High Titre Antibody: A Case Report

Cinzia Vio

Transfusion and Immunohematology Service, University Hospital, Padua, Italy.

Anna Colpo

Transfusion and Immunohematology Service, University Hospital, Padua, Italy.

Luca Collodel

Transfusion and Immunohematology Service, Dell’ Angelo General Hospital, Mestre, Venice, Italy.

Piero Marson

Transfusion and Immunohematology Service, University Hospital, Padua, Italy and Department of Transfusion Medicine, Padua Prefecture, Italy.

Gianluca Gessoni *

Transfusion and Immunohematology Service, Dell’ Angelo General Hospital, Mestre, Venice, Italy and Department of Transfusion Medicine, Venice Prefecture, Italy.

*Author to whom correspondence should be addressed.


Abstract

Background: Few reports have been published about  the current clinical management of anti-Kell alloimmunization in pregnancy; its low frequency of occurrence means that the few long series published have covered an extensive time period in which different treatment approaches have overlapped. The objective of the present paper is to present our experience in the clinical management of a pregnant woman who was positive for the anti-Kell antibody.

Materials and Methods: The laboratory follow-up included the weekly measurement of the antibody titre, and identification of the paternal and fetal genotype. The clinical management included TPE and IVIG administration. Obstetric monitoring included ultrasonographic monitoring of the fetus.

Case Description:  We report a case of anti-Kell alloimmunization with high antibody titre at first observation.  Testing for fetal DNA circulating in maternal blood confirmed positivity for KEL1 gene. The patient underwent fifteen sessions of TPE after  18 weeks of gestational age, followed by weekly IVIG infusion, which continued until 27 weeks of pregnancy. Anti-Kell titres were measured before and after each TPE session.

The patient had no need for IUBT and delivered by cesarean section at 34 weeks of gestational age.  Pregnancy resulted in a live birth with mild HDFN.

Discussion: HDFN is a potentially lethal complication of alloimmunization, and IUBT is the standard treatment for severe fetal anemia. TPE and IVIG are two alternative treatment modalities described in the literature to avoid or postpone the need for IUBT transfusion. In the case reported, despite any substantial change in antibody titre, pregnancy resulted in a live birth. This result suggests that the use of TPE and IVIG in alloimmunization during pregnancy could be an effective treatment strategy.

Keywords: Anti-Kell, hemolytic disease of fetus and newborn, therapeutic plasma exchange, pregnancy


How to Cite

Vio, Cinzia, Anna Colpo, Luca Collodel, Piero Marson, and Gianluca Gessoni. 2024. “Positive Outcome in a Pregnancy With Anti-Kell Alloimmunization Treated With Intravenous Immunglobulin and Therapeutic Plasma Exchange Despite Persistence of High Titre Antibody: A Case Report”. International Blood Research & Reviews 15 (3):1-6. https://doi.org/10.9734/ibrr/2024/v15i3339.

Downloads

Download data is not yet available.

References

Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen facts book. Third Edition, Elsevier, London; 2012.

Schenkel-Brunner H. Human blood groups, chemical and biochemical basis of antigen specificity. Third Edition, Spinger, Wien; 2012.

Gessoni G. Immunohematology. In: Clinical and Laboratory Medicine Textbook, Ciaccio M Editor. First edition, Springer, London; 2024.

Moise Jr KJ. Red blood cell alloimmunization in pregnancy. InSeminars in hematology WB Saunders. 2005;42(3): 169-178.

Sun JB. The prenatal intervention of pregnancy complicated with anti-Kell isoimmunization: a review. The Journal of Maternal-Fetal & Neonatal Medicine. 2021;34(17):2893-9.

Caine ME, Mueller-Heubach E. Kell sensitization in pregnancy. Am J Obstet Gynecol. 1986;154:85-90.

DOI: 10.1016/0002-9378(86)90398-4.

Mayne KM, Bowell PJ, Pratt GA. The significance of anti-Kell sensitization in pregnancy. Clin Lab Haematol. 1990;12: 379-85. DOI: 10.1111/j.1365-2257.1990.tb00349.x

Awowole I, Cohen K, Rock J, Sparey C. Prevalence and obstetric outcome of women with red cell antibodies in pregnancy at the leeds teaching hospitals nhs trust, West Yorkshire, England. Eur J Obstet Gynecol Reprod Biol. 2019;237: 89-92. DOI: 10.1016/j.ejogrb.2019.04.016

Vaughan JI, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IA. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med. 1998; 338: 798-803. doi: 10.1056/NEJM199803193381204.

Santiago JC, Ramos-Corpas D, Oyonarte S, Montoya F. Current clinical management of anti-Kell alloimmunization in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2008; 136:151-4. DOI: 10.1016/j.ejogrb.2007.03.003.

Hosseini MS, Jafari L, Shiri Heris R, Gharehbaghian A. Red blood cell alloimmunization in Iran: A Comprehensive review of the literature. Asian J Transfus Sci. 2020;14: 4-8. DOI: 10.4103/ajts.AJTS_137_17

Connelly-Smith L, Alquist C, Aqui N. Guidelines on the use of therapeutic apheresis in clinical practice – evidence-based approach from the writing committee of the American society for apheresis. J Clin Apher. 2023;138:77-278. DOI: 10.1002/jca.22043

Grant SR, Kilby MD, Meer L, Weaver JB, Gabra GS, Whittle MJ. The outcome of pregnancy in Kell alloimmunisation. BJOG. 2000;107:481-5. DOI: 10.1111/j.1471-0528.2000.tb13266.x

McKenna DS, Nagaraja HN, O'Shaughnessy R. Management of pregnancies complicated by anti-Kell isoimmunization. Obstet Gynecol. 1999;93: 667-73. DOI: 10.1016/s0029-7844(98)00491-8.

Flesiopoulou I, Pouliakis A, Politou M, Dourouki A, Damaskos C, Koutsouri T, Papakonstantinou M, Soulakis V, Tsantes A, Valsami S. Red blood cell alloantibody titration - Does the titration method matter? Clin Lab. 2020;66. DOI: 10.7754/Clin.Lab.2019.191021

Weiner CP, Widness JA. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am J Obstet Gynecol. 1996;174:547-51. DOI: 10.1016/s0002-9378(96)70425-8.

PMID.

Goh JT, Kretowicz EM, Weinstein S, Ramsden GH. Anti-Kell in pregnancy and hydrops fetalis. Aust N Z J Obstet Gynaecol. 1993;33:210-1. DOI: 10.1111/j.1479-828x.1993.tb02397.x.

Patris M, Holoye A, Goldman D, De Coninck C, Colard M. Successful management of severe Kell alloimmunization in pregnancy with intravenous immune globulin. Transfus Apher Sci. 2024;63:103868. DOI: 10.1016/j.transci.2023.

Colpo A, Marson P, Pavanello F, Tison T, Gervasi MT, Zambon A, Ruffatti A, De Silvestro G, Hoxha A. Therapeutic apheresis during pregnancy: A single center experience. Transfus Apher Sci. 2019;58:652-658. DOI: 10.1016/j.transci.2019.07.009.